Regeneron's Libtayo approved in Japan for cervical cancer
Mohammed Haneefa Nizamudeen         

Japanese regulators have granted marketing authorization to Regeneron's (NASDAQ:REGN) LibtayoÂ (cemiplimab) forÂ advanced or recurrent cervical cancer.
Approval was based on the results of the phase 3 EMPOWER-Cervical 1 trial which enrolled participants regardless of PD-L1 expression status.
In Q3 2022, Libtayo recorded worldwide sales of $126M.
Read why Seeking Alpha contributor ONeil Trader rates Regeneron (REGN) a buy.